Bronchodilators Market Size by Drug Class, Route Of Administration, Disease, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032
Overview
Bronchodilators Market size was valued at USD 23.1 Bn. in 2025 and expected to grow by 4.1% from 2026 to 2032, reaching nearly USD 30.6 Bn.
Global Bronchodilators Market Overview:
Bronchodilators are inhaled and are used to treat breathing disorders, such as asthma or emphysema. The bronchodilators market is witnessing growth due to factors such as the growing geriatric population, increasing prevalence of lung diseases, and rising awareness about lung disease treatment aided by escalating R&D efforts by key players operating in the market. The growing geriatric population globally is expected to act as a key driver for the market as the elderly population has a five times higher mortality rate attributed to asthma and thus requires enhanced support from bronchodilators. Moreover, the number of people aged over 65 is anticipated to triple by 2026 and is projected to aid the bronchodilators market to become profitable.
The development of advanced products is majorly driven by the rising prevalence of respiratory disorders worldwide. Bronchodilators help in relieving the symptoms of respiratory disorders such as asthma and COPD, by opening the airways and counteracting the effects of an attack. This is causing a surge in product approval and launches for treating and managing respiratory disorders which is estimated to supplement the segment growth. The growth of the bronchodilators market is the key parameter resulting in a gradual decrease in the functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market.
To know about the Research Methodology :- Request Free Sample Report
Global Bronchodilators Market Dynamics:
Bronchodilators Market Thrives on Growing Geriatric Population and Increasing Prevalence of Lung Diseases, Boost by R&D Efforts of Key Players
The bronchodilators market is witnessing growth due to factors such as the growing geriatric population, increasing prevalence of lung diseases, and rising awareness about lung disease treatment aided by escalating R&D efforts by key players operating in the market. The growing geriatric population globally is expected to act as a key driver for the market as the elderly population has a five times higher mortality rate attributed to asthma and thus requires enhanced support from bronchodilators. The development of advanced products is majorly driven by the rising prevalence of respiratory disorders worldwide. Bronchodilators help in relieving the symptoms of respiratory disorders such as asthma and COPD, by opening the airways and counteracting the effects of an attack. This is causing a surge in product approval and launches for treating and managing respiratory disorders which is estimated to supplement the segment growth. The growth of the bronchodilators market is the key parameter resulting in a gradual decrease in the functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market.
Global Bronchodilators Market Opportunity-
Bronchodilators Market Sees Opportunities with Growing Prevalence of Respiratory Disorders and Increasing Disposable Income Worldwide
The increasing prevalence of respiratory disorders such as asthma and COPD, as well as the rise in the incidence of respiratory diseases due to cigarette smoking, are driving the demand for bronchodilators. This trend is expected to continue in the coming years, creating opportunities for companies operating in the bronchodilators market. Moreover, the rise in disposable income and the growing geriatric population are also contributing to the growth of the bronchodilators market. As people become more affluent, they are more likely to seek medical treatment for respiratory disorders. Additionally, the aging population is at a higher risk of developing respiratory diseases, which is expected to drive demand for bronchodilators in the coming years.
The bronchodilators market presents significant opportunities for companies to expand their product offerings and increase their market share. Companies that are able to effectively address the needs of patients with respiratory disorders are well-positioned to capitalize on these opportunities and achieve long-term growth.
Global Bronchodilators Market Restraints-
Bronchodilators Market Hindered by Stringent Regulatory Framework and Shortage of Albuterol Inhalers
The market is significantly hampered owing to the regulatory framework related to bronchodilators. The regulatory approval procedure is frequently critiqued for being excessively slow or lenient when safety issues arise. The regulatory atmosphere is already complex, and the FDA is becoming ever more careful as dependency on bronchodilators is growing. Hence, the stringency of regulations associated with the approval process for bronchodilators is limiting the market growth.
Global Bronchodilators Market Segmentation:
Based on Drug Class: Beta-adrenergic dominated the bronchodilator Market in 2025 and is expected to continue its dominance during the forecast period Beta-adrenergic bronchodilators relax the muscles that surround the airways for dilating bronchial airways. This class of medications is beta-2 agonists and targets smooth muscle cell receptors for the dilation of airways. Major products in the short-acting category include levalbuterol (Xopenex HFA), albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin HFA), and epinephrine injection. Albuterol is the major revenue-generating molecule in this category and an increasing number of generic approvals and new launches are being observed for this molecule by FDA to meet the rising demands.
Global Bronchodilators Market Regional Insights:
North America dominated the bronchodilators market in 2025, which is attributed to the increasing prevalence of COPD and asthma, a rising geriatric population, and increasing demand for high-efficacy and fast-acting drugs in the region. The rising COPD cases in the region is attributed to air pollution, working with chemicals, dust and fumes, second-hand smoke, and a history of childhood lung infection. According to the American Lung Association, cigarette smoking is responsible for 85 to 90% of all COPD cases. The region has a high number of smokers which is estimated to be 30.8 million adults in the U.S. and more than 16 million people living in the region are suffering from smoking-related diseases.
Recent Industry Developments (2025–2026)
| Exact Date | Company | Development | Impact |
|---|---|---|---|
| 11 January 2025 | AstraZeneca | The U.S. FDA granted approval for Airsupra (albuterol/budesonide) to treat and prevent bronchoconstriction. | This approval introduces the first anti-inflammatory rescue inhaler to the U.S. market, reducing the risk of severe asthma exacerbations. |
| 22 May 2025 | GSK plc | The U.S. FDA approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD. | This marks a major expansion of biologic therapies for COPD patients with an eosinophilic phenotype, addressing over one million potential patients in the U.S. |
| 16 July 2025 | Aer Therapeutics | The company secured $36 million in Series A financing to advance its novel inhaled small molecule AER-01 into Phase I clinical trials. | The funding accelerates development of a first-in-class mucolytic drug designed to liquefy mucus plugs, a primary cause of airway obstruction in COPD. |
| 23 July 2025 | Harbour BioMed | Partner Windward Bio initiated the POLARIS global Phase 2 clinical study for HBM9378, a long-acting anti-TSLP antibody. | The study aims to provide a best-in-class maintenance therapy for asthma and COPD with a lower risk of immunogenicity and improved bioavailability. |
| 01 October 2025 | Merck & Co. | Merck completed a $10 billion acquisition of Verona Pharma to integrate its respiratory therapy portfolio. | This acquisition strengthens Merck's position in the respiratory market by adding Ohtuvayre (ensifentrine), a novel dual PDE3/PDE4 inhibitor. |
| 14 February 2026 | GSK plc | GSK entered into a licensing agreement with Empirico for the development of siRNA oligonucleotide therapies. | The collaboration focuses on identifying genetically validated targets to develop next-generation precision medicines for COPD treatment. |
Global Bronchodilators Market Scope: Inquire before buying
| Bronchodilators Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 23.1 USD Bn |
| Forecast Period 2026-2032 CAGR: | 4.1% | Market Size in 2032: | 30.6 USD Bn |
| Segments Covered: | by Drug Class | Beta-Adrenergic Bronchodilators Xanthine Derivatives Anticholinergic Bronchodilators |
|
| by Route Of Administration | Oral Nasal (Inhalable) Injectable |
||
| by Disease | Asthma Chronic Obstructive Pulmonary Disease (COPD) Others |
||
| by Distribution Channel | Retail Pharmacies Hospital Pharmacies E-Commerce Drug Stores |
||
Bronchodilators Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
South America (Brazil, Argetina and Rest of South America)
Key players/competitors profile covered in Bronchodilator Market report in strategic perspective
GlaxoSmithKline plc
AstraZeneca
Boehringer Ingelheim International GmbH
Novartis AG
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Sanofi S.A.
Cipla Ltd.
Viatris Inc.
Sun Pharmaceutical Industries Ltd.
Chiesi Farmaceutici S.p.A.
Hikma Pharmaceuticals PLC
Lupin Limited
Amneal Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Limited
Sandoz International GmbH
Bayer AG
Johnson & Johnson
Amgen Inc.
Kyowa Kirin Co., Ltd.
Verona Pharma plc
Aerami Therapeutics
Innoviva, Inc.
Mylan N.V.